Trial profile

1. Trial profile John A Dormandy et al. Lancet 2005;366:1279-89

2. Baseline characteristics John A Dormandy et al. Lancet 2005;366:1279-89

3. Macrovascular morbidity at study entry and associated medications John A Dormandy et al. Lancet 2005;366:1279-89

4. Kaplan-Meier curve of time to primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

5. Kaplan-Meier curve of time to main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

6. Numbers of first events contributing to the primary composite and main secondary endpoints John A Dormandy et al. Lancet 2005;366:1279-89

7. Effect of pioglitazone and placebo on each component of the primary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

8. Hazard associated with relevant baseline characteristics for the main secondary endpoint John A Dormandy et al. Lancet 2005;366:1279-89

9. Change in proportion of patients using concomitant medications John A Dormandy et al. Lancet 2005;366:1279-89

10. Kaplan-Meier curve of time to permanent insulin use John A Dormandy et al. Lancet 2005;366:1279-89

11. Change in laboratory data from baseline to final visit John A Dormandy et al. Lancet 2005;366:1279-89

12. Serious adverse event summary John A Dormandy et al. Lancet 2005;366:1279-89

13. Reports of heart failure John A Dormandy et al. Lancet 2005;366:1279-89